Choriocarcinoma and partial hydatidiform moles

Seckl, Michael J.; Fisher, Rosemary A.; Salerno, Giovanni; Rees, Helen C.; Paradinas, F. J.; Foskett, Marianne; Newlands, E. S.

doi:10.1016/s0140-6736(00)02432-6

Cited by 321 publications

(158 citation statements)

References 5 publications

Supporting

Mentioning

141

Contrasting

Unclassified

Order By: Relevance

“…In this case one pulmonary metastasis was resected and histology confirmed choriocarcinoma. Genetic analysis was carried out using fluorescent Pregnancy and relapse after trophoblastic disease SP Blagden et al microsatellite genotyping as previously described (Seckl et al, 2000) in order to determine the causative pregnancy. The results shown in Table 4 demonstrate that the choriocarcinoma arose from the preceding complete mole.…”

Section: Resultsmentioning

confidence: 99%

The effect of early pregnancy following chemotherapy on disease relapse and foetal outcome in women treated for gestational trophoblastic tumours

et al. 2002

View full text Add to dashboard Cite

Little literature exists on the safety of early pregnancy following chemotherapy. Here we assess the rate of relapse and foetal outcome in women who have completed single and multi-agent chemotherapy for gestational trophoblastic tumours. The records of 1532 patients treated for persistent gestational trophoblastic tumours at Charing Cross Hospital between 1969 and 1998 were reviewed. Patients were defined as receiving single agent or multi-agent treatment. Relapse rates and foetal outcome were reviewed in the 230 patients who became pregnant within 12 months of completing chemotherapy. In the single agent group 153 (22%) of 691 patients conceived early. Three subsequently relapsed. In the multi-agent group, 77 (10%) of 779 patients conceived early, two then relapsed. Relapse rates were 2% (3 out of 153) and 2.5% (2 out of 77) for each group compared to 5% and 5.6% in the comparative non-pregnant groups. Outcomes of 230 early pregnancies: 164 (71%) delivered at full term, 35 (15%) terminations, 26 (11%) spontaneous abortions, three (1.3%) new hydatidiform moles and two (1%) stillbirths. Early pregnancies were more common in the single agent group (P50.001), but spontaneous miscarriages and terminations were more likely to occur in the multi-agent group (P=0.04 and 0.03, respectively). Of the fullterm pregnancies, three (1.8%) babies were born with congenital abnormalities. Patients in either group who conceive within 12 months of completing chemotherapy are not at increased risk of relapse. Though, we still advise avoiding pregnancy within 12 months of completing chemotherapy, those that do conceive can be reassured of a likely favourable outcome.

show abstract

Section: Resultsmentioning

confidence: 99%

The effect of early pregnancy following chemotherapy on disease relapse and foetal outcome in women treated for gestational trophoblastic tumours

et al. 2002

View full text Add to dashboard Cite

show abstract

“…PCR amplification of nine short tandem repeat loci from eight different chromosomes (chromosomes 2,3,4,5,7,11,12,13) and the amelogenin locus (for XY determination) was performed, with thermal cycling conditions and capillary electrophoresis carried out according to the manufacturer's instructions (AmpFlSTR Profiler kit; Applied Biosystems; Foster City, CA). In certain selected situations (see results), an expanded analysis with PCR amplification of 15 short tandem repeat loci from 13 different chromosomes (chromosomes 2, 3,4,5,7,8,11,12,13,16,18,19,21) and the amelogenin locus (for XY determination) was performed (AmpFlSTR Identifiler kit; Applied Biosystems). The PCR conditions were 95 1C for 11 min followed by 28 cycles of 94 1C for 1 min, 59 1C for 1 min, and 72 1C for 1 min, followed by a final extension at 60 1C for 45 min.…”

Section: Diagnosis Of Hydatidiform Molesmentioning

confidence: 99%

Characteristics of hydatidiform moles: analysis of a prospective series with p57 immunohistochemistry and molecular genotyping

et al. 2014

View full text Add to dashboard Cite

Immunohistochemical analysis of cyclin-dependent kinase inhibitor 1C (CDKN1C, p57, Kip2) expression and molecular genotyping accurately classify hydatidiform moles into complete and partial types and distinguish these from non-molar specimens. Characteristics of a prospective series of all potentially molar specimens encountered in a large gynecologic pathology practice are summarized. Initially, all specimens were subjected to both analyses; this was later modified to triage cases for genotyping based on p57 results: p57-negative cases diagnosed as complete hydatidiform moles without genotyping; all p57-positive cases genotyped. Of the 678 cases, 645 were definitively classified as complete hydatidiform mole (201), partial hydatidiform mole (158), non-molar (272), and androgenetic/biparental mosaic (14); 33 were unsatisfactory, complex, or problematic. Of the 201 complete hydatidiform moles, 104 were p57-negative androgenetic and an additional 95 were p57-negative (no genotyping), 1 was p57-positive (retained maternal chromosome 11) androgenetic, and 1 was p57-non-reactive androgenetic; 90 (85%) of the 106 genotyped complete hydatidiform moles were monospermic and 16 were dispermic. Of the 158 partial hydatidiform moles, 155 were diandric triploid, with 154 p57-positive, 1 p57-negative (loss of maternal chromosome 11), and 1 p57-non-reactive; 3 were triandric tetraploid, with 2 p57-positive and 1 p57-negative (loss of maternal chromosome 11). Of 155 diandric triploid partial hydatidiform moles, 153 (99%) were dispermic and 2 were monospermic. Of the 272 non-molar specimens, 259 were p57-positive biparental diploid, 5 were p57-positive digynic triploid, 2 were p57-negative biparental diploid (no morphological features of biparental hydatidiform mole), and 6 were p57-non-reactive biparental diploid. Of the 14 androgenetic/biparental mosaics with discordant p57 expression, 6 were uniformly mosaic and 8 had a p57-negative androgenetic molar component. p57 expression is highly correlated with genotyping, serves as a reliable marker for diagnosis of complete hydatidiform moles, and identifies androgenetic cell lines in mosaic conceptions. Cases with aberrant and discordant p57 expression can be correctly classified by genotyping.

show abstract

“…This risk is higher than in CHM patients (20 %) [10] or PHM patients (4-11 %) [11,12]. It has now been demonstrated that the risk of PGTD is not reduced even if pregnancy is terminated early instead of being allowed to continue to term.…”

Section: Discussionmentioning

confidence: 99%

Complete Hydatidiform Mole with Coexisting Twin Fetus: Usefulness of MRI in Management Planning

Bajaj

Misra

Gupta

et al. 2013

J Obstet Gynecol India

View full text Add to dashboard Cite

Choriocarcinoma and partial hydatidiform moles

Cited by 321 publications

References 5 publications

The effect of early pregnancy following chemotherapy on disease relapse and foetal outcome in women treated for gestational trophoblastic tumours

The effect of early pregnancy following chemotherapy on disease relapse and foetal outcome in women treated for gestational trophoblastic tumours

Characteristics of hydatidiform moles: analysis of a prospective series with p57 immunohistochemistry and molecular genotyping

Complete Hydatidiform Mole with Coexisting Twin Fetus: Usefulness of MRI in Management Planning

Contact Info

Product

Resources

About